Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib versus tocilizumab in children with systemic juvenile idiopathic arthritis
2023-507883-38-00Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2024
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 16
01
Overview
Phase 3, randomised, open-label trial of baricitinib in systemic juvenile idiopathic arthritis (SJIA) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Percentage of participants achieving adapted Pediatric ACR30 (PediACR30) response at Week 12. Started Feb 2024; status: completed.
02
Drugs
baricitinib
03
Conditions
systemic juvenile idiopathic arthritis (SJIA)
Beyond the preview
Go deeper on 2023-507883-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507883-38-00.